CAPITOL HILL CONSULTING GROUP

Lobbying for TEVA PHARMACEUTICALS USA · Generic and biosimilar manufacturer.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Health Issues

Issues surrounding US Pharmaceutical supply chain. Issues surrounding the generic drug and biosimilar user free agreements. Issues surrounding the regulation of complex generic drugs. Issues related to Inflation Reduction Act.

Medicare/Medicaid

Issues surrounding Medicare reimbursement of generic drugs and biosimilars. Issues relating to the impact of prescription drug negotiation on generic drugs. Issues related to drug shortages. Issues related to drug pricing including drug negotiation.

Trade (domestic/foreign)

Issues related to potential tariffs on generic drugs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.